The FDA granted accelerated approval to talquetamab-tgvs for treatment of certain patients with relapsed or refractory multiple myeloma.
The indication authorizes use of the agent for adults who received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.
Talquetamab-tgvs (Talvey, Janssen) — administered as a weekly or biweekly subcutaneous injection — is a first-in-class bispecific antibody. It binds to the CD3 receptor on the surface of T cells and G protein-coupled receptor class C group 5 member D on the
